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1. Introduction 
Several method used when an initial filtering procedure is not adequate to control the 
refractory glaucoma and when resumption of medical therapy,revision of original surgery, 
repeat filtering surgery at a new site, or aqueous shunt implantation is not successful; finally 
all cyclodestructive procedures reduce aqueous secretion by destroying part of the secretory 
ciliary epithelium portion of the ciliary body including cyclocryotherapy, contact and non-
contact trans-scleral thermal lasers such as continuous-wave with the 1064-nm Nd:YAG, 
argon, and portable 810-nm semiconductor Diode laser.1-4 Cryotherapy, the original 
technique, is increasingly being supplanted by laser photocoagulation, originally with the 
1064-nm Nd:YAG laser and lately with the portable 810-nm semiconductor Diode laser.2-3 
An endoscopic laser delivery system has been advocated for use with cataract surgery or in 
pediatric, pseudophakic, or aphakic eyes. Use of the argon laser aimed at the ciliary 
processes through a goniolens is possible in a small percentage of patients. Transcleral diod 
laser cyclophotocoagulation (CPC ) reducing aqueous secretion by destroying, is generally 
considered to be better tolerated and perhaps more effective than cyclocryotherapy, and it 
has a lower incidence of complications such as postoperative pain, inflammation, phthisis 
bulbi and retinal detachment, possibly because of better absorption of this wave length by 
the pigmented tissues of the ciliary body. Diode laser cyclophotocoagulation (CPC) is often 
the choice treatment of lOP-lowering in painful blind eyes or in eyes unlikely to respond to 
other modes of therapy. Interventions methods such as retrobulbar alcohol injection, 
retrobulbar chlorpromazine injection, or enucleation are rarely performed now because of 
improved CPC techniques. Treatment of glaucoma in the pediatric population is frequently 
 challenging and may require multiple surgical interventions. In the past it was used mainly 
in uncontrolled end-stage secondary glaucoma with minimal visual potential mainly to 
control pain. However it is now apparent that it can also be used in eyes with reasonably 
good vision which may be retained provided control of IOP is adequate. This section studies 
the indications, success rate and long term efficacy and complications of the cyclodestructive 
procedures in refractory glaucoma. Laser cycloablation is generally considered to be better 
tolerated and perhaps more effective than cyclocryotherapy.3,4 The most commonly used 
technique for cyclodestructive surgery is the transscleral approach, in which the destructive 
element must pass through conjunctiva, sclera, and ciliary musculature, before reaching and 
destroying the ciliary processes. These procedures have the advantages of being 
noninvasive and relatively quick and easy because of variable success in adults (34-92%) 
and significant postoperative pain and complications including phthisis and retinal 
detachment, transscleral neodymium:YAG (Nd:YAG) and Diode lasers are replacing 
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cyclocryotherapy as the preferred form of cyclodestruction in these eyes.5-7 The 
cyclophotocoagulation has a lower incidence of complications such as pain, postoperative 
inflammation and phthisis bulbi, possibly because of better absorption of this wave length 
by the pigmented tissues of the ciliary body.7-9 Several methods of Diode laser 
photocyclocoagulation have been reported to lower IOP and reduce pain in the eyes of 
refractory glaucoma Diode cyclophotocoagulation and sequential tube shunt following 
primary tube shunt failure in childhood glaucoma showed similar efficacy and complication 
rates. Ten to fifty percent of patients with primary congenital glaucoma fail goniotomy 
surgery and require further surgical intervention, Childhood glaucoma associated with 
systemic or ocular anomalies and secondary glaucoma such as that associated with 
congenital aphakia or pseudophakia have a worse surgical prognosis compared to primary 
congenital glaucoma. Trabeculectomy surgery with adjunctive mitomycin has a lower 
chance of successful control of children less than two years of age and in children who have 
had congenital cataract surgery. Additionally, compared to adults, the adjunctive use of 
anti-fibrotic agents with trabeculectomy in children may be associated with greater risk of 
late bleb-related infections. When a tube shunt fails to adequately control the intraocular 
pressure, limited treatment options remain. These options include a sequential tube shunt in 
another quadrant of the eye revision or replacement of the existing tube shunt, or a 
cyclodestructive procedure (usually transscleral or endoscopic Diode cyclophotocoagulation 
or cyclocryotherapy). Both tube shunts and transscleral Diode cyclophotocoagulation have 
been examined for treatment of refractory pediatric glaucoma. Compare the results of 
Contact Diod Laser Cyclophotocoagulation Versus Cyclocryotherapy in Refractory 
Glaucoma.10 -15  
Ciliary ablation is indicated to lower lOP in eyes that have glaucoma resistant to 
conventional medical and surgical therapies (refractory glaucoma, neovascular glaucoma, 
congenital glaucoma, secondary glaucoma, Post-surgical glaucoma, poor visual potential or 
that are poor candidates for incisional surgery(because of the small risk of sympathetic 
ophthalmia), painful blind eyes or in eyes unlikely to respond to other modes of therapy 
were treated with transscleral Diode laser Cyclophotocoagulation (CPC). 
Ciliary ablation is relatively contraindicated in eyes with good vision because of the risk of 
loss of visual acuity.  
Preoperative evaluation is the same as for incisional glaucoma surgery. 
2. Methods and considerations 
All patients signed an informed consent for the Ciliary body ablation procedures, after an 
explanation of the risks and benefits. Cyclophotocoagulation was performed under local 
anaesthesia (A sub-Tenon or peri bulbar ) with the Laser settings arc 1.5-2 sec and 1500-
2000 mW with semiconductor Diode laser system (810 nm laser wavelength) with a 
spherical polished tip oriented by a handpiece, “G-Probe.”. Figures 1 and 2. Duration was 
set at 2000 ms (2 seconds), and the initial power setting was 1750 MW. After the edge of the 
probe is aligned with the limbus, approximately 17-19 applications are placed 270° around 
the limbus, with a power of 1.5-2 Wand a duration of approximately 2 seconds The power 
was increased in 250 MW increments to a maximum of 2000 MW until an audible 'popping' 
sound is heard, and then the power was reduced by 250 MW to just below that level. 
Approximately 2-40 burns arc (typically five per quadrant for 270 degrees of treatment) 
placed 1.2 mm posteriorly to the limbus over 180 ºbut avoiding the posterior ciliary nerves 
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at 3 and 9 o'clock. In all cases, the probe tips were carefully examined. The Diode laser 
handpiece attachment from one manufacturer is shown in figure 2. A strong topical steroid 
is prescribed hourly on the day of treatment and then q.i.d. for 2 weeks. Oral non-steroidal 
anti-inIlammatory agents are prescribed for 2 days. Figure 1 showed cyclodestructive 
procedures to relieve pain. Figure 2 showed Semiconductor Diode laser. Figure 3 showed 
‘‘G probe’’ handpiece for contact Diode TCP.  
 
 
Fig. 1. Cyclodestructive procedures to relieve pain 
 
 
Fig. 2. Semiconductor Diode laser (IRIS Oculight SLx, Iris Medical Inc) for Diode contact TCP 
 
 
Fig. 3. Showed ‘‘G probe’’ handpiece for contact Diode TCP 
Frequently more than one treatment session is required for adequate pressure control. The 
outcome of cycloDiode therapy was determined in terms of: 
1. Success rate: defined as the percentage of eyes achieving and IOP between 5 and 21mm 
Hg with or without topical medication with cessation of oral carbonic anhydrase 
inhibitor use in all eyes after cycloDiode therapy at their final follow-up visit. 
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2. Response rate: defined as the percentage of patients achieving >30% drop from baseline 
IOP with cessation of oral carbonic anhydrase inhibitor use. This included eyes that 
developed hypotony (IOP<5mm Hg). 
3. Failure rate: defined as percentage of patients who developed hypotony (IOP<5mm Hg) 
or phthisis, or those whose IOP drop was <30% from baseline. 
The success rate is dependent on the type of glaucoma, frequently more than one treatment 
session is required for adequate pressure control and the procedure has to be repeated. Pain 
relief is generally good. After surgery intra ocular pressure and mean number of antiglaucoma 
medications would be dropped. 
Criteria for success included intraocular pressure (IOP) of 21 mmHg or less with no 
devastating complications or need for further glaucoma surgery. 
Pain following these procedures may be substantial, and patients should be provided with 
adequate analgesics, including narcotics, during the immediate postoperative period. 
Cyclophotocoagulation may be associated with vision loss, prolonged hypotony, pain, 
inflammation, cystoid macular edema, hemorrhage, and even phthisis bulbi. Sympathetic 
ophthalmia is a rare but serious complication. Mildpostoperative pain and anterior segment 
innammation are common. Serious complications are rare and include conjunctival burns, 
prolonged uveitis, hyphema, chronic hypotony, phthisis bulbi, scleral thinning, corneal 
decompensation and retinal or choroidal detachment. However, since the aim of the 
procedure is usually to relieve pain. Vision-threatening complications do not have the same 
significance as those following conventional filtering procedures.  
Transscleral Diode laser cycloablation is a recognized therapeutic approach to refractory 
glaucoma that involves photocoagulation of the pars plicata of the ciliary body with 
consequent reduction of aqueous secretion.7,11 Diode laser cyclophotocoagulation appeared 
to be an effective and safe primary surgical treatment of medically uncontrolled chronic 
angle closure glaucoma, with intraocular pressure lowering effect persisting for up to two 
years.16 
TSCPC has a significant ocular hypotensive effect on glaucoma refractory to both tube shunt 
and medical therapy.17 
An unqualified success after cycloablation would be the attainment of a target IOP  
without the need for further medication, coupled with preservation of visual function. 
CycloDiode therapy appears to be effective in lowering IOP, in both the short and long term. 
Endoscopic cyclophotocoagulation (ECP) was introduced as an alternative to trans-scleral 
cyclophotocoagulation for treating refractory glaucomas in order to minimise complications 
such as phthisis and hypotony by providing direct visualisation of the ciliary processes. 
Glaucoma following penetrating keratoplasty, which has an incidence ranging from 10–52%, 
often proves refractory to medical treatment.1–3 We introduce a case of refractory post-PKP 
glaucoma in order to demonstrate the efficacy of ECP in treating post-PKP glaucoma and  
to describe its potential delayed effect in achieving intraocular pressure control Diode Laser 
Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Medically Uncontrolled 
Chronic Angle Closure Glaucoma Long-Term Clinical Outcomes.17 Endoscopic 
cyclophotocoagulation (ECP) was introduced as an alternative to trans-scleral 
cyclophotocoagulation for treating refractory glaucomas in order to minimise complications 
such as phthisis and hypotony by providing direct visualisation of the ciliary processes. 
Glaucoma following penetrating keratoplasty, which has an incidence ranging from 10–52%, 
often proves refractory to medical treatment.1–3 We introduce a case of refractory post-PKP 
glaucoma in order to demonstrate the efficacy of ECP in treating post-PKP glaucoma and to 
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describe its potential delayed effect in achieving intraocular pressure control Diode Laser 
Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Medically Uncontrolled 
Chronic Angle Closure Glaucoma Long-Term Clinical Outcomes Diode Laser Transscleral 
Cyclophotocoagulation for Refractory Glaucoma.18 
Contact Diode laser transscleral cyclophotocoagulation is useful in eyes with refractory 
glaucoma in which the risks of outflow surgery are deemed unacceptable, Diode laser 
transscleral cyclophotocoagulation (DCPC) is one of the most widely used methods of 
ciliary body ablation, with reported success rates ranging from 40% to 80% cyclodestructive 
procedures are generally reserved for eyes with glaucoma refractory to other forms of 
medical or surgical intervention. In the past 10 years, cyclocryotherapy has been replaced by 
other techniques, especially laser cyclophotocoagulation with Nd:YAG or Diode laser 
systems,5–10 that achieve good results with a lower complication rate.19-24 Diode laser 
transscleral cyclophotocoagulation is effective in lowering the intraocular pressure in 
chronic angle-closure glaucoma and its effect lasts for at least 1 year.20 Transscleral Diode 
laser cyclophotocoagulation is an effective and safe method for the treatment of advanced, 
refractory glaucoma. However, repeated treatments are often necessary. Success of treatment 
depends on the age of patients, previous surgery, and the type of glaucoma.21 Types of 
glaucoma that are often difficult to treat include neovascular glaucoma, posttraumatic 
glaucoma, glaucoma associated with aphakia severe congenital/developmental glaucoma, 
postretinal surgery glaucoma, glaucoma associated with penetrating keratoplasties, and 
glaucoma in eyes with scarred conjunctiva from surgery or disease processes.22 Delgado et 
al. (2003) reported that use of noncontact transscleral neodymium:yttrium-aluminum-garnet 
cyclophotocoagulation for NVG in 115 eyes, while providing long-term IOP reduction, was 
associated with complications that included inflammation, visual loss, and hypotony, and 
that repeat treatments may be necessary to main good control of IOP.27 Table 1showed 
demographics and treatment results of Transscleral diode laser cyclophotocoagulation at the 
different studies.  
 
Reference 
number 
Successfully 
treated eyes 
(%) 
Follow-
up (mos) 
Age (yrs) 
(range) 
No. of 
eyes (%) 
 
19 74.2% 12 9–92 93 A. Mistlberger et al 
15 89% 17 4–99 263 Mr J P Diamond et al 
17 28.6 17.1 92-22  32 Ness et al 
9 34.1 34.1  34 Bloom et al 
13 66.7% 12 1-15 9 Sood and Beck 
16 92.3% 12 76 -48  14 Jimmy et al 
21 74.2% 12 9–92 93 T. Schlote et al. 
24 94.4%) 12 38–100 47 
F. A. Hauber and W. J. 
Scherer 
25 84% 23.1 6–90 53 
Ataullah, Biswas, Artes, 
et al 
26 69.5% 30.1 84-69  131 Iliev, Gerber 
Table 1. Demographics and treatment results of Transscleral diode laser 
cyclophotocoagulation at the different studies  
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Previous studies have demonstrated this, with ocular hypotensive responses.7-9 Our study 
showed that in 50.6 % of patients the IOP was below 21 mmHg. 
Complications of transscleral Diode CPC include conjunctival surface burns that may occur 
if tissue debris becomes coagulated on the tip and chars. We inspected all tips for this and 
found no debris. In addition, increased perilimbal conjunctival pigmentation may occur. 
One of patients had hypotony and phthisis after treatment 21 months after treatment. The 
risks of hypotony and phthisis are directly proportional to the dosage of laser energy 
delivered in a treatment session,7 although, a clear relationship between treatment energy 
and IOP response, which is essential to accurate prediction of desirable effect, remains to be 
demonstrated. The published literature suggests that this type of treatment is usually 
reserved for eyes with end stage disease and poor visual potential. In conclusion, this study 
showed an increase of visual acuity after transscleral Diode laser cyclophotocoagulation 
therapy. Diode laser cyclophotocoagulation produces very characteristic injury to pars 
plicata, which frequently extends into pars plana, but with only mild persisting 
inflammation. Ciliary processes are, however, frequently spared within the treatment zone 
and may account for early or late treatment failure.22-24 
Histopathological studies of enucleation specimens following laser cyclophotocoagulation 
(Diode and Nd:YAG laser) and cyclocryotherapy have been performed in humans 25–29 and 
animals.12, 30–35 We have previously reported histopathology of two cases of clinical failure 
following Diode laser cyclophotocoagulation.36 This study examines histological outcomes 
in nine cases in humans, and correlates this with the clinical c course in each eye.28 Repeated 
use of the G-probe in transscleral cyclophotocoagulation, with ethylene oxide sterilization in 
between, resulted in an average decrease of 3% in laser energy delivered per repeated cycle 
of use up to the fourth cycle. No signs of physical damage were found.25-28 
Laser G-probes remain functional after repeated use and ethylene oxide resterilization for 
up to four cycles. No visible physical damage to the probes was identified. It is safe and 
cost-effective to reuse G-probe for transscleral cyclophotocoagulation with ethylene oxide 
sterilization, provided the surgeon stays alert for signs of probe damage. This alertness 
should be retained regardless of whether new or old G-probes are used.29-30 We noticed 
microscopic contamination of the G-probe by the tear film fluid in all the probes examined 
by us. The review of literature indicates that repeated use of the G-probe is not uncommon. 
The types of techniques used for making it suitable for repeated use indicate that it is not 
universally recognized that the lumen of the G-probe can accumulate fluid during the 
procedure, which makes it potentially hazardous when used for other patients. 
Treatment with cyclophotocoagulation in patients with refractory glaucoma leads to 
increase in acuity and lower intraocular pressure. In our opinion the G-probe should not be 
reused as inadequately reprocessed G-probe can lead to risk of nosocomial infections, 
serious iatrogenic complications, and medico-legal problems.30 Underlying diagnosis of 
neovascular glaucoma is a significant risk factor for hypotony post TCP. Hypotony was 
defined as IOP <5 at the end of 1-year follow-up period. Factors, such as underlying 
diagnosis, total energy used, age, earlier operations, and retreatment rates, which may 
influence the development of hypotony were analyzed using univariate analysis.31 -32 
CycloDiode therapy is highly effective but there is a significant risk of hypotony, which may 
be reduced by applying lower energy in cases of very high pretreatment IOP and in 
neovascular glaucoma.The dose-response association remains unpredictable, although a 
linear relation was found for neovascular glaucoma. Cyclophotocoagulation is necessary in 
some intractable cases but should be avoided whenever possible because of its potential 
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adverse effects on the lens and the retina. retrobulbar alcohol injection, retrobulbar 
chlorpromazine injection, or enucleation are rarely performed now because of improved 
CPC techniques. 
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